TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Apogeotropic Horizontal Canal Benign Paroxysmal Positional Vertigo

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. history of vertigo associated with changes in head position~2. direction-changing horizontal nystagmus beating toward the uppermost ear (apogeotropic nystagmus) in both turning positions detected with Frenzel glasses or videoculography in the Head turning test~3. vertigo associated with the elicited nystagmus~4. symptom within 2 weeks~5. put one's signature on consent~Exclusion Criteria:~1. patients with identifiable central nervous system disorders that could explain the positional vertigo and nystagmus~2. the patients with apogeotropic form which was transited from geotropic after previous therapeutic maneuvers~3. the patients who transited from apogeotropic from vertical canal BPPV during study~4. patients who had possible cause of secondary BPPV such as Meniere's disease, migraine or recent trauma history~5. patients whose affected ear cannot be identified~6. patients with multiple canal atypical positional nystagmus or who were treated previously with repositioning maneuvers were excluded.~7. patients with cervical or lumbar spine problem

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Gufoni (Type: EXPERIMENTAL): Gufoni maneuver for apogeotropic horizontal BPPV at the first day
- Vibration (Type: EXPERIMENTAL): Vibration maneuver for apogeotropic horizontal BPPV at the first day
- Sham (Type: SHAM_COMPARATOR): Sham maneuver for apogeotropic horizontal BPPV at the first day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: RESILIENT: A Research Study, Looking at How Ryzodeg® Works in People With Type 2 Diabetes in Local Clinical Practice in Japan

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Informed consent obtained before any study-related activities. Study-related activities are any procedures related to recording of data according to the protocol~* The decision to initiate treatment with commercially available insulin Ryzodeg® has been made by the patient/legally acceptable representative and the treating physician before and independently from the decision to include the patient in this study~* Male or female, age more than or equal to 20 years (the legal age of adulthood) at the time of signing informed consent~* Diagnosed with type 2 diabetes (T2D) for at least 26 weeks prior to signing informed consent~* Available and documented glycosylated haemoglobin (HbA1c) value less than or equal to 12 weeks prior to initiation of Ryzodeg® treatment~* For at least 26 weeks prior to initiation of Ryzodeg® treatment, one of the following must apply: A) Treated with insulin glargine (IGlar) (any formulation, including biosimilar IGlar). B) Treated with IGlar (any formulation, including biosimilar IGlar) and IGlar U300 for at least 12 weeks prior to initiation of Ryzodeg®~Exclusion Criteria:~* Previous participation in this study. Participation is defined as signed informed consent.~* Pregnancy~* Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation~* Hypersensitivity to Ryzodeg® or to any of the excipients~* Previously treated with Ryzodeg®

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patients with Type 2 Diabetes requiring insulin therapy (Type: None): Patients with type 2 diabetes requiring insulin therapy in Japanese routine clinical practice previously treated with insulin glargine (IGlar)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Increasing Patching for Amblyopia in Children 3 to < 8 Years Old

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Major Eligibility Criteria for Run-in Phase~* Age 3 to \< 8 years~* Amblyopia associated with strabismus, anisometropia, or both~* Visual acuity in the amblyopic eye between 20/50 and 20/400 inclusive~* Visual acuity in the sound eye 20/32 or better and inter-eye acuity difference \>3 logMAR lines~* Amblyopia treatment within the past 6 months subject to the following stipulations:~  * No more than 6 weeks of any amblyopia treatment other than spectacles (except for patients being treated with 2 hours of patching per day who are entering the study on treatment)~ * No simultaneous treatment with patching and atropine~ * No use of atropine in combination with the sound eye spectacle lens reduced by more than 1.50 D~ * Maximum level of treatment within the past 6 months:~    * Patching: up to 2 hours daily~   * Atropine: up to once daily~* Wearing spectacles with optimal correction (if applicable); if amblyopic eye acuity is 20/80 or better, then VA must be stable in glasses. If amblyopic eye acuity is 20/100 or worse, then spectacles and patching can be initiated simultaneously.~Eligibility Criteria for Randomization:~* Amblyopic eye acuity of 20/40 to 20/160 with an inter-ocular difference of \>2 lines, or amblyopic eye acuity of 20/32 with 3 lines of IOD.~* Reasonable compliance with prescribed treatment, defined as wearing the patch at least 10 hours per week.~Exclusion Criteria:~* Currently using vision therapy or orthoptics~* Ocular cause for reduced visual acuity (nystagmus per se does not exclude the patient if the above visual acuity criteria are met)~* Prior intraocular or refractive surgery~* Known skin reaction to patch or bandage adhesives

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 7 Years
- Healthy Volunteers: f

Study Arms:
- Control (Type: ACTIVE_COMPARATOR): 2 hours daily patching
- Intensified treatment (Type: ACTIVE_COMPARATOR): 42 hours per week of patching (averaging 6 hours daily)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Telephone Support for Metastatic Breast Cancer Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient is at least 3 weeks post-diagnosis of stage IV breast cancer and is receiving care at the Indiana University (IU) Simon Cancer Center, Eskenazi Health, IU Health North, IU Health Bloomington, IU Health Ball Memorial, IU Health Portland, IU Health Morgan, IU Health New Castle, IU Health Central-Fishers, another IU Health hospital or clinic, Community Health Network, or the Robert H. Lurie Comprehensive Cancer Center of Northwestern University.~* Patient is at least 18 years of age.~* Patient has adequate English fluency for completion of data collection.~* Patient has moderate to severe fatigue interference with functioning~Exclusion Criteria:~* Patient shows significant psychiatric or cognitive impairment that would preclude providing informed consent and study participation.~* Patient reports being able to do little activity on a functional status measure.~* Patient is receiving hospice care at screening.~* Patient does not have working phone service.~* Patient has hearing impairment that precludes participation.~* Male sex

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Acceptance and Commitment Therapy (Type: EXPERIMENTAL): Patients in the ACT arm will learn new and more adaptive ways to respond to fatigue.
- Education/Support (Type: ACTIVE_COMPARATOR): Patients in the education/support arm will discuss their cancer-related concerns and receive education on services available in their medical center and community.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy, Safety, and Tolerability of Atogepant for the Prevention of Chronic Migraine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* At least a 1-year history of chronic migraine (CM) consistent with a diagnosis according to the International Classification of Headache Disorders, 3rd Edition (ICHD-3), 2018~* Age of the participant at the time of migraine onset \< 50 years~* Confirmation of headache/migraine headache day frequency as follows:~  * History of, on average, ≥ 15 headache days per month in the 3 months prior to Visit 1 in the opinion of the investigator AND~ * \>=15 headache days during the 4-week screening/baseline period per the electronic diary (eDiary) AND~ * \>=8 days during the 4-week screening/baseline period that qualify as being a migraine day per the eDiary~* Participants must be using a medically acceptable and effective method of birth control during the course of the entire study~Exclusion Criteria:~* Has a history of migraine, accompanied by diplopia or decreased level of consciousness, or retinal migraine~* Has a current diagnosis of new persistent daily headache, trigeminal autonomic cephalgia (eg, cluster headache), or painful cranial neuropathy~* History of an inadequate response to \> 4 medications (2 of which have different mechanisms of action) prescribed for the prevention of migraine~* Woman is pregnant, planning to become pregnant during the course of the study, or currently lactating. Women of childbearing potential must have a negative urine pregnancy test at Visit 1 and Visit 2.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Participants received atogepant-matching placebo tablets, orally, twice daily (BID) for 12 weeks in a double-blind (DB) treatment period.
- Atogepant 30 mg BID (Type: ACTIVE_COMPARATOR): Participants received atogepant 30 mg tablet, orally, BID and atogepant-matching placebo tablets orally, BID for up to 12 weeks in a DB treatment period.
- Atogepant 60 mg QD (Type: ACTIVE_COMPARATOR): Participants received atogepant 60 mg, orally, once daily (QD) along with atogepant-matching placebo 30 mg as morning dose followed by atogepant-matching placebo 30 mg and 60 mg as evening doses for up to 12 weeks in a DB treatment period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trial to Evaluate the Efficacy and Safety of OC-01 (Varenicline) Nasal Spray on Signs and Symptoms of Dry Eye Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Have used and/or desired to use an artificial tear substitute for dry eye symptoms within 6 months prior to the Screening Visit~Exclusion Criteria:~* Have had any intraocular surgery (such as cataract surgery) or extraocular surgery in either eye within three months or refractive surgery (e.g., laser-assisted in-situ keratomileusis, laser epithelial keratomileusis, photorefractive keratectomy or corneal implant) within 12 months of the Screening Visit~* Have a history or presence of any ocular disorder or condition in either eye that would, in the opinion of the Investigator, likely interfere with the interpretation of the study results or participant safety such as significant corneal or conjunctival scarring; pterygium or nodular pinguecula; current ocular infection, acute conjunctivitis, or inflammation not associated with dry eye; anterior (epithelial) basement membrane corneal dystrophy or other clinically significant corneal dystrophy or degeneration; ocular herpetic infection; evidence of keratoconus; etc. Blepharitis not requiring treatment and mild meibomian gland disease that are typically associated with DED are allowed.~* Have a systemic condition or disease not stabilized or judged by the Investigator to be incompatible with participation in the study (e.g., current systemic infection, uncontrolled autoimmune disease, uncontrolled immunodeficiency disease, history of myocardial infarction or heart disease, etc.)~* Have a known hypersensitivity to any of the procedural agents or investigational product components~* Have any condition or history that, in the opinion of the investigator, may interfere with study compliance, outcome measures, safety parameters, and/or the general medical condition of the subject.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- OC-01 (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Behavioral Therapy in Patients With Rumination

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Rome IV criteria for rumination syndrome fulfilled~* gastroscopy, esophageal HR-manometry and 24-hour pH-impedance monitoring performed before referral to study~Exclusion Criteria:~* eating disorder, BMI \<14, pregnancy, cognitive or other disorder that disallows behavioral therapy

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Behavioral therapy (Type: EXPERIMENTAL): Behavioral therapy consisting of diaphragmatic breathing exercises and physiotherapy to relax tensed abdominal and thoracic muscles

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Hospital to Home Outcomes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient is under 18 years of age Patient is admitted to Cincinnati Children's Hospital Medical Center to hospital medicine, community pediatrics, adolescent medicine, neurology or neurosurgery.~Exclusion Criteria:~* Patient to be discharged someplace other than home (e.g., residential facility, psychiatric facility)~* Patient's home residence is outside the home nursing service area~* Patient is eligible for traditional home nursing services~* Caregiver is non-English speaking

- Gender: ALL
- Minimum Age: None
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Home Nurse Visit (Type: EXPERIMENTAL): Families in this arm will receive a nurse home visit within 96 hours of discharge.
- Control (Type: ACTIVE_COMPARATOR): This arm will receive standard of care.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Long-Term Safety of M207 in the Acute Treatment of Migraine

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Main Inclusion Criteria:~1. Women or men 18 to 75 years of age~2. Greater than 1 year history of episodic, migraine (with or without aura) with onset prior to 50 years of age.~3. Migraine history during the prior 6 months must include:~   1. at least 2 migraines per month~  2. no more than 8 migraines per month~  3. no more than 15 headache days per month~4. Women of child-bearing potential must not be pregnant, must agree to avoid pregnancy and use an acceptable double-barrier method of birth control during the trial.~5. Willing and able to treat a minimum of 2 migraines per month with study medication and consistently complete eDiary for up to 12 months.~Main Exclusion Criteria:~1. Contraindication to triptans~2. Use of selective serotonin reuptake inhibitors (drugs like Prozac®) or serotonin or norepinephrine reuptake inhibitors (drugs like Effexor®) or anti-coagulants (drugs like Coumadin®)~3. Known allergy or sensitivity to zolmitriptan or its derivatives or formulations~4. Known allergy or sensitivity to adhesives and/or titanium~5. Women who are pregnant, breast-feeding or plan a pregnancy during this study~6. Three or more of the following cardiovascular risk factors:~   * Current tobacco use~  * Hypertension or receiving anti-hypertensive medication for hypertension~  * Hyperlipidemia or on prescribed anti-cholesterol treatment~  * Family history of premature coronary artery disease~  * Diabetes mellitus~7. History or current abuse or dependence on alcohol or drugs

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- M207 Microneedle System 3.8 mg (Type: EXPERIMENTAL): M207 Microneedle System 3.8 mg (1.9 mg/patch x 2 patches)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study on Spermatogenesis in Male Renal Transplant Recipients Receiving Valganciclovir (Valcyte®) Versus Untreated Matched Controls

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* First renal transplant~* Participant eligible to receive valganciclovir prophylaxis as determined by the treating physician in accordance with the local approved product prescribing information (Cohort A only) or the participant is not expected to require any valganciclovir prophylaxis (Cohort B only) post-transplant~* Participant has no history of known infertility~* Participant is able and willing to provide semen samples~* Participant agrees to utilize a barrier contraceptive throughout the study or for at least 90 days after cessation of valganciclovir treatment~Exclusion Criteria:~* Prior ganciclovir or valganciclovir within 3 months of enrollment~* Organ transplant other than kidney~* Participant has received an investigational new drug in the 3 months prior to transplant~* Participant hs received an alkylating agent or other medications known to affect fertility/spermatogenesis~* Participant is unlikely to be available for follow-up for the entire duration of the study (up to 52 weeks)

- Gender: MALE
- Minimum Age: 20 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Cohort A: Partcipants who Received Valganciclovir (Type: EXPERIMENTAL): Participants with donor positive (D+)/recipient negative (R-) cytomegalovirus (CMV) serology, who receive valganciclovir prophylaxis according to the local prescribing information, will be observed for spermatogenesis up to 52 weeks post-transplant.
- Cohort B: Untreated Participants (Type: NO_INTERVENTION): Participants with donor negative (D-)/R- CMV serology, who do not receive prophylaxis, will be observed for spermatogenesis up to 52 weeks post-transplant.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Involving Family to Improve Communication in Primary Care

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Older adults: 65 years or older, established patient of participating primary care provider, regularly attend medical visits with one or more family member or unpaid friend companion(s), agree to allow companion to be contacted and participate in the study, authorize disclosure of Protected Health Information (PHI) in their electronic health record, able to provide informed consent or have a legally authorized representative~* Companion: family member (spouse, adult child, parent, adult sibling) or unpaid friend who accompanies older adult participant to medical visits.~* Primary care provider: practicing physician, nurse practitioner or physician assistant at a participating primary care practice.~Exclusion Criteria:~* Older adults: younger than 65 years, no evidence of cognitive impairment, do not attend medical visits with family member or unpaid friend.~* Companion: paid non-family member who accompanies patient to visits

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Checklist (Type: EXPERIMENTAL): One-page paper-pencil agenda setting checklist involving two activities for older primary care patients and their family companion. The purpose of the checklist is to 1. clarify the role of the family companion during the visit, and 2. to discuss patient health issues to discuss with the primary care provider
- Usual Care (Type: PLACEBO_COMPARATOR): Care as usual with their primary care provider

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete